BioMarin/$BMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioMarin
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Ticker
$BMRN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
3,040
ISIN
US09061G1013
Website
BioMarin Metrics
BasicAdvanced
$11B
20.44
$2.70
0.30
-
Price and volume
Market cap
$11B
Beta
0.3
52-week high
$94.85
52-week low
$52.93
Average daily volume
2.4M
Financial strength
Current ratio
5.52
Quick ratio
3.202
Long term debt to equity
10.281
Total debt to equity
10.281
Interest coverage (TTM)
59.46%
Profitability
EBITDA (TTM)
803.618
Gross margin (TTM)
79.74%
Net profit margin (TTM)
17.76%
Operating margin (TTM)
24.25%
Effective tax rate (TTM)
22.31%
Revenue per employee (TTM)
$970,000
Management effectiveness
Return on assets (TTM)
6.38%
Return on equity (TTM)
9.64%
Valuation
Price to earnings (TTM)
20.435
Price to revenue (TTM)
3.563
Price to book
1.83
Price to tangible book (TTM)
1.98
Price to free cash flow (TTM)
16.951
Free cash flow yield (TTM)
5.90%
Free cash flow per share (TTM)
325.47%
Growth
Revenue change (TTM)
19.36%
Earnings per share change (TTM)
152.30%
3-year revenue growth (CAGR)
16.22%
10-year revenue growth (CAGR)
13.93%
3-year earnings per share growth (CAGR)
132.76%
10-year earnings per share growth (CAGR)
9.51%
What the Analysts think about BioMarin
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
Bulls say / Bears say
BioMarin Pharmaceutical reported a 28% year-over-year revenue growth in Q3 2024, with total revenues reaching $746 million, indicating strong financial performance. (stocktitan.net)
The company's VOXZOGO® (vosoritide) treatment for achondroplasia demonstrated significant height improvements in children, with real-world data showing an average increase of 6.36 cm after 12 months and 11.86 cm after 24 months, supporting its efficacy and market potential. (stocktitan.net)
Analysts have shown confidence in BioMarin's prospects, with Barclays maintaining a 'Buy' rating and setting a price target of $110.00 as of September 2024. (markets.businessinsider.com)
BioMarin's stock reached a new 52-week low of $68.73 in September 2024, reflecting potential investor concerns about the company's valuation. (marketbeat.com)
The company announced a global workforce reduction of approximately 225 employees in September 2024, which may indicate internal challenges or cost-cutting measures that could impact operations. (reuters.com)
BioMarin faces competition from Ascendis Pharma's TransCon CNP, which offers once-weekly dosing for achondroplasia, potentially affecting BioMarin's market share for VOXZOGO®. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BioMarin Financial Performance
Revenues and expenses
BioMarin Earnings Performance
Company profitability
BioMarin News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioMarin stock?
BioMarin (BMRN) has a market cap of $11B as of July 01, 2025.
What is the P/E ratio for BioMarin stock?
The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 20.44 as of July 01, 2025.
Does BioMarin stock pay dividends?
No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next BioMarin dividend payment date?
BioMarin (BMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for BioMarin?
BioMarin (BMRN) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.